1例重症患者抗感染个体化给药策略分析

石晓萍; 吕迁洲; 杨婉花; 方洁

doi:10.3969/j.issn.1006-0111.2017.06.018

1例重症患者抗感染个体化给药策略分析

doi: 10.3969/j.issn.1006-0111.2017.06.018

1.
复旦大学附属中山医院药剂科, 上海 200032
2.
上海交通大学医学院附属瑞金医院药剂科, 上海 200025

The individualized anti-infective treatment strategy for a critically ill patient

1.
Department of Pharmacy, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, China
2.
Department of Pharmacy, Ruijin Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China

摘要: 目的探讨对于重症感染的患者如何根据其特殊的病理生理状况制订个体化抗感染治疗方案。方法临床药师参与1例急性泛发性发疹性脓疱病继发血流感染和肺部感染患者的抗感染治疗，通过分析其病理生理状况，运用治疗药物监测，协助临床医生制订个体化的给药方案。结果患者初始抗感染治疗方案效果不佳，临床药师根据患者的个体情况和血药浓度监测结果调整给药方案，患者的感染得到控制，病情好转。结论确保重症患者给药剂量达到药动学/药效学目标值是治疗成功的关键。
- 急性泛发性发疹性脓疱病 /
- 药物监测 /
- 万古霉素 /
- 阿米卡星
Abstract: Objective To design individualized anti-infective therapy for a critically ill patient. Methods Based on pathophysiological conditions and therapeutic drug levels,clinical pharmacists assisted physicians to optimize individual anti-infective medication regimens for a patient with acute generalized exanthematous pustulosis secondary to blood stream infection and pulmonary infection. Results The patient responded poorly to initial treatment. After the medication regimen adjustments byclinical pharmacists according to the individual situation and therapeutic drug monitoring results,patient's condition was improved and the infection was under control. Conclusion The key to successful treatment is to ensure the dosage administered to the critically ill patients reach the target value of pharmacokinetics and pharmacodynamics.
- acute generalized exanthematous pustulosis /
- therapeutic drug monitoring /
- vancomycin /
- amikacin

[1]	Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children[J]. Clin Infect Dis, 2011,52(3):e18-e55.
[2]	Truong J, Levkovich BJ, Padiglione AA. Simple approach to improving vancomycin dosing in intensive care:a standardised loading dose results in earlier therapeutic levels[J]. Intern Med J, 2012,42(1):23-29.
[3]	万古霉素临床应用剂量专家组. 万古霉素临床应用剂量中国专家共识[J]. 中华传染病杂志, 2012,30(11):641-646.
[4]	桑德福. 热病:桑德福抗微生物治疗指南[M]. 范洪伟译. 44版.北京:中国协和医科大学出版社, 2014:96-109.
[5]	Martin JH, Norris R, Barras M, et al. Therapeutic monitoring of vancomycin in adult patients:a consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists[J]. Clin Biochem Rev, 2010,31(1):21-24.
[6]	van Hal SJ, Fowler VJ. Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?[J]. Clin Infect Dis, 2013,56(12):1779-1788.
[7]	Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill:challenges and potential solutions[J]. Lancet Infect Dis, 2014,14(6):498-509.
[8]	Rostas SE, Kubiak DW, Calderwood MS. High-dose intravenous vancomycin therapy and the risk of nephrotoxicity[J]. Clin Ther, 2014,36(7):1098-1101.
[9]	Arimura Y, Yano T, Hirano M, et al. Mitochondrial superoxide production contributes to vancomycin-induced renal tubular cell apoptosis[J]. Free Radic Biol Med, 2012,52(9):1865-1873.
[10]	Mulazimoglu L, Drenning SD, Yu VL. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis[J]. Antimicrob Agents Chemother, 1996,40(10):2428-2430.
[11]	Jacqueline C, Caillon J, Le Mabecque V, et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods[J]. J Antimicrob Chemother, 2003,51(4):857-864.
[12]	Singh SR, Bacon AR, Young DC, et al. In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus[J]. Antimicrob Agents Chemother, 2009,53(10):4495-4497.
[13]	Chiang FY, Climo M. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus[J]. Antimicrob Agents Chemother, 2003,47(9):3002-3004.
[14]	Beibei L, Yun C, Mengli C, et al. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections:meta-analysis of randomised controlled trials[J]. Int J Antimicrob Agents, 2010,35(1):3-12.
[15]	穆玉, 范春芳, 朱铁梁, 等. 重症患者利奈唑胺所致血小板减少危险因素分析[J]. 中国感染与化疗杂志, 2012,12(1):10-14.
[16]	Kalil AC, Metersky ML, Klompas M, et al. Executive summary:management of adults with hospital-acquired and ventilator-associated pneumonia:2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society[J]. Clin Infect Dis, 2016,63(5):575-582.
[17]	Zelenitsky SA, Harding GK, Sun S, et al. Treatment and outcome of Pseudomonas aeruginosa bacteraemia:an antibiotic pharmacodynamic analysis[J]. J Antimicrob Chemother, 2003,52(4):668-674.
[18]	Kato H, Hagihara M, Hirai J, et al. Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen[J]. Drugs RD, 2017,17(1):177-187.
[19]	Duszynska W, Taccone FS, Hurkacz M, et al. Therapeutic drug monitoring of amikacin in septic patients[J]. Crit Care, 2013,17(4):R165.
[20]	付双双, 唐惠林, 段京莉. 抗感染药物治疗药物监测的Meta分析[J]. 中国新药杂志, 2013,22(15):1840-1848.
[21]	梅清, 喻婷, 朱玉林, 等. 万古霉素单用及联合利福平或磷霉素对耐甲氧西林金黄色葡萄球菌防耐药突变浓度的研究[J]. 中国药理学通报, 2011,27(7):944-947.
[22]	胡文, 邓国泉, 伍婷, 等. 万古霉素单用与联用磷霉素治疗耐甲氧西林金黄色葡萄球菌肺部感染的疗效比较[J]. 实用中西医结合临床, 2012,12(4):6-7.
[23]	中华医学会呼吸病学分会《雾化吸入疗法在呼吸疾病中的应用专家共识》制定专家组. 雾化吸入疗法在呼吸疾病中的应用专家共识[J]. 中华医学杂志, 2016,96(34):2696-2708.

[1]	张紫璇, 高苑, 张利, 李佳莉, 徐希科, 祖先鹏. 中药防治急性肺损伤的活性成分及其作用机制研究进展 . 药学实践与服务, 2025, 43(): 1-7. doi: 10.12206/j.issn.2097-2024.202404079
[2]	郭静, 康金龙, 李强, 赵琳, 刘骥, 徐学武. 利多卡因不同给药途径对麻醉诱导气管插管心血管应激反应的抑制作用 . 药学实践与服务, 2025, 43(6): 303-306. doi: 10.12206/j.issn.2097-2024.202502009
[3]	郭灵怡, 刘艳超, 高路, 刘瑞瑶, 吕权真, 俞媛. 醋酸卡泊芬净单硬脂酸甘油酯纳米粒抗白色念珠菌感染的增效作用研究 . 药学实践与服务, 2025, 43(3): 136-142, 150. doi: 10.12206/j.issn.2097-2024.202310043
[4]	李锐, 张倩倩, 王瑞冬, 高小峰. 国家集中带量采购政策下样本医院良性前列腺增生治疗药物使用情况分析 . 药学实践与服务, 2025, 43(1): 41-46. doi: 10.12206/j.issn.2097-2024.202408031
[5]	姜建芳, 王思平, 何新军. 硝苯地平在高血压孕妇中的药物毒性：基于FARES数据库的真实世界研究 . 药学实践与服务, 2025, 43(6): 307-312. doi: 10.12206/j.issn.2097-2024.202501001
[6]	曹金发, 钟玲, 何苗, 田泾. 炎症性肠病合并心房颤动患者的用药分析与监护 . 药学实践与服务, 2025, 43(): 1-4. doi: 10.12206/j.issn.2097-2024.202403004
[7]	张岩, 李炎君, 刘家荟, 邓娇, 原苑, 张敬一. 药物性肝损伤不良反应分析 . 药学实践与服务, 2025, 43(1): 26-29, 40. doi: 10.12206/j.issn.2097-2024.202404034
[8]	晁亮, 王辉, 沈淑琦, 游飘雪, 冀凯宏, 洪战英. 基于UHPLC-Q/TOF-MS代谢组学策略的葛根-知母药对防治阿尔茨海默病的药效与作用机制研究 . 药学实践与服务, 2025, 43(1): 30-40. doi: 10.12206/j.issn.2097-2024.202409035
[9]	王彦, 康乐, 陈文, 方琦, 俞仲望, 曹莉. 基于CiteSpace结合系统评价方法分析药品不良反应自动监测系统的热点及优势 . 药学实践与服务, 2025, 43(): 1-8. doi: 10.12206/j.issn.2097-2024.202501034
[10]	徐璐璐, 刘爱军. 丹参白术方“异病同治”冠心病、血管性痴呆、特发性膜性肾病的网络药理学作用机制研究 . 药学实践与服务, 2025, 43(3): 143-150. doi: 10.12206/j.issn.2097-2024.202312027
[11]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(12): 512-519. doi: 10.12206/j.issn.2097-2024.202401050
[12]	王鹏, 陈顺, 赵逸, 高守红, 王志鹏. 卡培他滨致小鼠手足综合征模型的建立及评价 . 药学实践与服务, 2024, 42(9): 385-388, 398. doi: 10.12206/j.issn.2097-2024.202308045
[13]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[14]	宋泽成, 陈林林, 鲁仁义, 刘梦肖, 王彦. 脓毒症治疗的研究进展 . 药学实践与服务, 2024, 42(11): 457-460, 502. doi: 10.12206/j.issn.2097-2024.202405059
[15]	夏哲炜, 曾垣烨, 朱海菲, 李育, 陈啸飞. 核磁共振磷谱法测定磷酸氢钙咀嚼片中药物含量 . 药学实践与服务, 2024, 42(9): 399-401, 406. doi: 10.12206/j.issn.2097-2024.202404063
[16]	陈怡君, 王卓, 何苗, 张宇, 田泾. 泌尿系统碎石术抗菌药物预防使用合理管控实践 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402034
[17]	张元林, 宋凯, 孙蕊, 舒飞, 舒丽芯, 杨樟卫. 基于真实世界数据的药物利用研究综述 . 药学实践与服务, 2024, 42(6): 238-243. doi: 10.12206/j.issn.2097-2024.202312010
[18]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[19]	何亚伦, 祁智, 常杰. 消胀通便膏在晚期肝癌患者阿片类药物相关性便秘中的应用研究 . 药学实践与服务, 2024, 42(12): 520-523. doi: 10.12206/j.issn.2097-2024.202309009
[20]	孙丹倪, 黄勇, 张嘉宝, 王培. 代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049

点击查看大图

计量

文章访问数: 3969
HTML全文浏览量: 470
PDF下载量: 630
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

1例重症患者抗感染个体化给药策略分析

doi: 10.3969/j.issn.1006-0111.2017.06.018

The individualized anti-infective treatment strategy for a critically ill patient

计量

1例重症患者抗感染个体化给药策略分析

doi: 10.3969/j.issn.1006-0111.2017.06.018

1. 复旦大学附属中山医院药剂科, 上海 200032

2. 上海交通大学医学院附属瑞金医院药剂科, 上海 200025

English Abstract

The individualized anti-infective treatment strategy for a critically ill patient

1. Department of Pharmacy, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, China

2. Department of Pharmacy, Ruijin Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China

全文HTML

目录

留言板

1例重症患者抗感染个体化给药策略分析

doi: 10.3969/j.issn.1006-0111.2017.06.018

The individualized anti-infective treatment strategy for a critically ill patient

计量

出版历程

1例重症患者抗感染个体化给药策略分析

doi: 10.3969/j.issn.1006-0111.2017.06.018

1. 复旦大学附属中山医院药剂科, 上海 200032 2. 上海交通大学医学院附属瑞金医院药剂科, 上海 200025

English Abstract

The individualized anti-infective treatment strategy for a critically ill patient

1. Department of Pharmacy, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, China 2. Department of Pharmacy, Ruijin Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China

全文HTML

目录

1. 复旦大学附属中山医院药剂科, 上海 200032

2. 上海交通大学医学院附属瑞金医院药剂科, 上海 200025

1. Department of Pharmacy, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, China

2. Department of Pharmacy, Ruijin Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China